Orchard Therapeutics North America is a biotechnology company that develops gene therapies. Its filings show it lobbies on newborn screening for a rare genetic disease called metachromatic leukodystrophy and on changes to the federal Recommended Uniform Screening Panel and related funding. It hired a lobbying firm and reported about $70,000 in lobbying since 2026 filings began.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DAVID CLEARY
The latest disclosures for this client.
THEGROUP DC, LLC
4TTHEGROUP DC, LLC
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THEGROUP DC, LLC
THEGROUP DC, LLC
RR